Skip to main content

Table 1 Prevalence of antibodies to HERV-K10 Gag and Pol peptides in different populations

From: Increased seroreactivity to HERV-K10 peptides in patients with HTLV myelopathy

  VBD LGLL HTLVt HTLVm HTLVn MS
Peptides #tested #pos (%) #tested #pos (%) #tested #pos (%) #tested #pos (%) #tested #pos (%) #tested #pos (%)
HERV-K10 Gag* 100 7(7) 53 0(0) 74 18(24) 16 14(88) 58 4(7) 83 9(11)
HERV-K10 Pol+ 100 0(0) 53 3(6) 74 21(28) 16 15(94) 58 6(10) 83 13(16)
  1. *HERV-K10 Gag VBD vs. LGLL, p = 0.047; VBD vs. all HTLV+, p = 0.001; VBD vs. HTLV + myelopathy, p = < 0.001: VBD vs. HTLV + non-myelopathy, p = 0.626; VBD vs. multiple sclerosis, p = 0.256; HTLV + myelopathy vs. HTLV + non-myelopathy, p = <0.001; HTLV + myelopathy vs. MS p = < 0.001.
  2. +HERV-K10 Pol VBD vs. LGLL, p = 0.040; VBD vs. all HTLV+, p = 0.001; VBD vs. HTLV + myelopathy, p = < 0.001: VBD vs. HTLV + non-myelopathy, p = 0.002; VBD vs. multiple sclerosis, p = < 0.001; HTLV + myelopathy vs. HTLV + non-myelopathy, p = <0.001; HTLV + myelopathy vs. MS, p = < 0.001.